These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 30547830)

  • 1. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
    Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
    BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study.
    Benachi A; Delahaye S; Leticee N; Jouannic JM; Ville Y; Costa JM
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):28-32. PubMed ID: 22386678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
    Szczepura A; Osipenko L; Freeman K
    BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
    Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
    Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotyping approach for non-invasive foetal RHD detection in an admixed population.
    Boggione CT; Luján Brajovich ME; Mattaloni SM; Di Mónaco RA; García Borrás SE; Biondi CS; Cotorruelo CM
    Blood Transfus; 2017 Jan; 15(1):66-73. PubMed ID: 27136427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.
    Manfroi S; Calisesi C; Fagiani P; Gabriele A; Lodi G; Nucci S; Pelliconi S; Righini L; Randi V
    Blood Transfus; 2018 Nov; 16(6):514-524. PubMed ID: 29757138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive prenatal rhesus D genotyping using cell-free foetal DNA.
    Rather RA; Dhawan V; Saha SC
    Indian J Med Res; 2019 Jul; 150(1):62-66. PubMed ID: 31571630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
    Kent J; Farrell AM; Soothill P
    BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
    Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
    Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
    BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fetal RHD in maternal plasma in prenatal follow-up].
    Dricot JF; Minon JM; Schaaps JP; Dewez P; Foidart JM
    Rev Med Liege; 2006 Dec; 61(12):820-6. PubMed ID: 17313118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RHD genotyping from maternal plasma: guidelines and technical challenges.
    Avent ND
    Methods Mol Biol; 2008; 444():185-201. PubMed ID: 18425481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
    Hawk AF; Chang EY; Shields SM; Simpson KN
    Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.